Roxanne Carfora
Family Medicine · Saint James, NYNPI 1932204922
Payments from drug & device makers
Across 149 payments — averaging $56.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Quidel Corporation$5K
- AbbVie$977
- Novo Nordisk$860
- Amgen$433
- Pfizer$218
- Amarin Pharma, Inc.$200
- plus $735 from 14 others
What the payments were for
- Speaking & faculty fees$1,50018%
- Food & beverage$3,42341%
- Education$3,52042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Quidel Corporation | 4 | $5,020 |
| AbbVie(2 entities) | 43 | $977 |
| Novo Nordisk | 47 | $860 |
| Amgen | 11 | $433 |
| Pfizer | 13 | $218 |
| Amarin Pharma, Inc. | 6 | $200 |
| Alfasigma USA, Inc. | 5 | $150 |
| Revance Therapeutics, Inc. | 2 | $128 |
| UCB, Inc. | 1 | $125 |
| Eisai Inc. | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Merz North America, Inc. | 1 | $37 |
| Merck | 2 | $36 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $26 |
| IBSA Pharma Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Vistapharm, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,443 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 152 | $228,590 |
| OzempicSemaglutide | 23 | $45,091 |
| XyostedTestosterone Enanthate | 18 | $16,643 |
| VascepaIcosapent Ethyl | 18 | $7,886 |
| Levothyroxine Sodium | 148 | $2,769 |
| SynthroidLevothyroxine Sodium | 42 | $2,274 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $1,850 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $1,707 |
| Ezetimibe | 42 | $1,201 |
| Omega-3 Acid Ethyl Esters | 12 | $1,185 |
| Nebivolol Hcl | 14 | $1,136 |
| Armour ThyroidThyroid,pork | 14 | $1,050 |
| Losartan Potassium | 59 | $823 |
| Bupropion XlBupropion Hcl | 18 | $647 |
| Escitalopram Oxalate | 21 | $617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $14 | $228,590152 claims |
| Novo NordiskOzempic | $860 | $45,09123 claims |
| AbbVieSynthroid, Armour Thyroid | $977 | $3,32456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Saint James
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.